| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 217,597 | 101,788 | ||
| Investments | 376,031 | 223,128 | ||
| Prepaid and other current assets | 6,168 | 10,353 | ||
| Total current assets | 599,796 | 335,269 | ||
| Property and equipment, net | 7 | 22 | ||
| Other assets | 144 | 433 | ||
| Total assets | 599,947 | 335,724 | ||
| Accounts payable | 1,121 | 3,164 | ||
| Accrued liabilities | 22,399 | 19,009 | ||
| Total current liabilities | 23,520 | 22,173 | ||
| Common stock, 0.0001 par value 500,000,000 shares authorized as of september30, 2025 and december31, 2024 78,969,459 and 49,821,915 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 8 | 6 | ||
| Additional paid-in capital | 1,001,354 | 701,548 | ||
| Accumulated deficit | -424,935 | -388,003 | ||
| Total stockholders equity | 576,427 | 313,551 | ||
| Total liabilities and stockholders equity | 599,947 | 335,724 | ||
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)